Below are the most recent publications written about "Neuroendocrine Tumors" by people in Profiles.
-
Dasari A, Shen C, Devabhaktuni A, Nighot R, Sorbye H. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. Oncologist. 2022 Apr 05; 27(4):299-306.
-
Erstad DJ, Dasari A, Taggart MW, Kaur H, Konishi T, Bednarski BK, Chang GJ. ASO Visual Abstract: Prognosis for Poorly Differentiated High-Grade Rectal Neuroendocrine Carcinomas. Ann Surg Oncol. 2022 04; 29(4):2549.
-
Morani AC, Gupta S, Elsayes KM, Mubarak AI, Khalaf AM, Bhosale PR, Sun J, Jensen CT, Kundra V. Performance of Multidetector Computed Tomography and Negative Versus Positive Enteric Contrast for Evaluation of Gastrointestinal Neuroendocrine Neoplasms. J Comput Assist Tomogr. 2022 May-Jun 01; 46(3):333-343.
-
Maxwell JE, Naraev B, Halperin DM, Choti MA, Halfdanarson TR. Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis. Ann Surg Oncol. 2022 May; 29(5):3072-3084.
-
Das S, Chauhan A, Du L, Thomas KE, Jacob A, Schad A, Jain S, Jessop A, Shah C, Eisner D, Cardin DB, Ciombor KK, Goff LW, Bradshaw M, Delbeke D, Sandler M, Ramirez RA, Berlin J. External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy. JAMA Netw Open. 2022 01 04; 5(1):e2144170.
-
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 11 25; 385(22):2036-2046.
-
Fahrmann JF, Wasylishen AR, Pieterman CRC, Irajizad E, Vykoukal J, Murage E, Wu R, Dennison JB, Krishna H, Peterson CB, Lozano G, Zhao H, Do KA, Halperin DM, Agarwal SK, Blau JE, Del Rivero J, Nilubol N, Walter MF, Welch JM, Weinstein LS, Vriens MR, van Leeuwaarde RS, van Treijen MJC, Valk GD, Perrier ND, Hanash SM. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab. 2021 11 19; 106(12):e4969-e4980.
-
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 12; 22(12):1752-1763.
-
Sarvepalli S, Husain NS. Paraneoplastic Achalasia Associated With Neuroendocrine Tumor. Am J Gastroenterol. 2021 11 01; 116(11):2306.
-
Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O'Toole D, Sundin A, Prasad V. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. J Neuroendocrinol. 2022 03; 34(3):e13040.